57543-41-6

Usage

InChI:InChI=1/C11H10O3/c1-13-10-3-2-4-11-9(10)5-8(6-12)7-14-11/h2-6H,7H2,1H3

Upstream product

• 700-44-7 6-methoxysalicylaldehyde 
• 57543-72-3 5-methoxy-2H-chromene-3-carbonitrile 
• 107-02-8 acrolein 

Relevant academic research and scientific papers

Benzopyran compounds and preparation method thereof as well as pharmaceutical composition and use of benzopyran compounds

The invention discloses benzopyran compounds as shown in a formula I, a preparation method of the benzopyran compounds, a composition containing the compounds, and use of the compounds in preparation of a farnesoid X receptor antagonist, a liver protection agent and medicines for preventing and treating hyperlipidemia and diabetes mellitus type II.

Synthesis and biological evaluations of chalcones, flavones and chromenes as farnesoid x receptor (FXR) antagonists

Farnesoid X receptor (FXR), a nuclear receptor mainly distributed in liver and intestine, has been regarded as a potential target for the treatment of various metabolic diseases, cancer and infectious diseases related to liver. Starting from two previously identified chalcone-based FXR antagonists, we tried to increase the activity through the design and synthesis of a library containing chalcones, flavones and chromenes, based on substitution manipulation and conformation (ring closure) restriction strategy. Many chalcones and four chromenes were identified as microM potent FXR antagonists, among which chromene 11c significantly decreased the plasma and hepatic triglyceride level in KKay mice.

Synthesis of robalzotan, ebalzotan, and rotigotine precursors via the stereoselective multienzymatic cascade reduction of α,β-unsaturated aldehydes

A stereoselective synthesis of bicyclic primary or secondary amines, based on tetralin or chroman structural moieties, is reported. These amines are precursors of important active pharmaceutical ingredients such as rotigotine (Neupro), robalzotan, and eba